BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25919147)

  • 1. Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review.
    Swartz JE; Pothen AJ; Stegeman I; Willems SM; Grolman W
    Cancer Med; 2015 Jul; 4(7):1101-16. PubMed ID: 25919147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
    Jonathan RA; Wijffels KI; Peeters W; de Wilde PC; Marres HA; Merkx MA; Oosterwijk E; van der Kogel AJ; Kaanders JH
    Radiother Oncol; 2006 Jun; 79(3):288-97. PubMed ID: 16730088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET.
    Grönroos TJ; Lehtiö K; Söderström KO; Kronqvist P; Laine J; Eskola O; Viljanen T; Grénman R; Solin O; Minn H
    BMC Cancer; 2014 Nov; 14():876. PubMed ID: 25421331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
    Eriksen JG; Overgaard J;
    Radiother Oncol; 2007 Jun; 83(3):383-8. PubMed ID: 17543403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
    De Schutter H; Landuyt W; Verbeken E; Goethals L; Hermans R; Nuyts S
    BMC Cancer; 2005 Apr; 5():42. PubMed ID: 15847702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.
    Ipenburg NA; Koole K; Liem KS; van Kempen PM; Koole R; van Diest PJ; van Es RJ; Willems SM
    Target Oncol; 2016 Feb; 11(1):17-27. PubMed ID: 26115874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
    Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
    Ou D; Garberis I; Adam J; Blanchard P; Nguyen F; Levy A; Casiraghi O; Gorphe P; Breuskin I; Janot F; Temam S; Scoazec JY; Deutsch E; Tao Y
    Radiother Oncol; 2018 Jan; 126(1):116-124. PubMed ID: 29079308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.
    Sun ZJ; Yu GT; Huang CF; Bu LL; Liu JF; Ma SR; Zhang WF; Liu B; Zhang L
    Oncotarget; 2016 Mar; 7(10):11651-63. PubMed ID: 26872381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
    Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.
    Boscolo-Rizzo P; Da Mosto MC; Rampazzo E; Giunco S; Del Mistro A; Menegaldo A; Baboci L; Mantovani M; Tirelli G; De Rossi A
    Cancer Metastasis Rev; 2016 Sep; 35(3):457-74. PubMed ID: 27501725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slug is a key mediator of hypoxia induced cadherin switch in HNSCC: correlations with poor prognosis.
    Zhang J; Cheng Q; Zhou Y; Wang Y; Chen X
    Oral Oncol; 2013 Nov; 49(11):1043-50. PubMed ID: 24035721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of hypoxia inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential.
    Cohen NA; Lai SY; Ziober AF; Ziober BL
    Laryngoscope; 2004 Mar; 114(3):418-23. PubMed ID: 15091212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinomas that overexpress hypoxia inducible factor-1α.
    Swartz JE; Pothen AJ; van Kempen PM; Stegeman I; Formsma FK; Cann EM; Willems SM; Grolman W
    Head Neck; 2016 Sep; 38(9):1338-46. PubMed ID: 27027530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma.
    Winter SC; Shah KA; Campo L; Turley H; Leek R; Corbridge RJ; Cox GJ; Harris AL
    Clin Cancer Res; 2005 Nov; 11(21):7614-20. PubMed ID: 16278379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
    Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.